Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PRECIGEN, INC.PGEN · Entity 4356 | President and CEO | August 23, 2026 | August 25, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PRECIGEN, INC.
Report date August 23, 2026 · Filed August 25, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 3,779,521 |
Ending reported balance
After 2026-08-23 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-08-23 · Exercise / conversion · Acquired 20,833 · Balance 3,789,705 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Precigen common stock. Row 2 · 2026-08-23 · Tax withholding · Disposed 10,184 · Balance 3,779,521 F2: Represents the number of shares of Precigen common stock withheld by the Issuer to satisfy income tax withholding obligations in connection with the settlement of the RSUs. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 229,167 |
Reported balance
After 2026-08-23 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-08-23 · Exercise / conversion · Disposed 20,833 · Balance 229,167 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Precigen common stock. F3: Represents 1/24 of the RSUs granted on June 26, 2025 that vested on August 23, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Precigen common stock.
F2: Represents the number of shares of Precigen common stock withheld by the Issuer to satisfy income tax withholding obligations in connection with the settlement of the RSUs.
F3: Represents 1/24 of the RSUs granted on June 26, 2025 that vested on August 23, 2026.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Kinnate Biopharma Inc.
Report date April 03, 2024 · Filed April 05, 2024
Section 16 reporting ended · disclosed 2024-04-05. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.38 · Expires 2031-06-24 | Direct | 0 |
Reported balance
After 2024-04-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-04-03 · Disposition to issuer · Disposed 40,501 · Balance 0 F1: This option was cancelled pursuant to that certain Agreement and Plan of Merger, dated February 16, 2024, by and between the Issuer, XOMA Corporation and XRA 1 Corp. (the "Merger Agreement") in exchange for one non-transferable contingent value right ("CVR") for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.48 · Expires 2033-06-12 | Direct | 0 |
Reported balance
After 2024-04-03 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-04-03 · Disposition to issuer · Disposed 25,000 · Balance 0 F1: This option was cancelled pursuant to that certain Agreement and Plan of Merger, dated February 16, 2024, by and between the Issuer, XOMA Corporation and XRA 1 Corp. (the "Merger Agreement") in exchange for one non-transferable contingent value right ("CVR") for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.38 · Expires 2032-06-13 | Direct | 0 |
Reported balance
After 2024-04-03 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-04-03 · Disposition to issuer · Disposed 20,250 · Balance 0 F1: This option was cancelled pursuant to that certain Agreement and Plan of Merger, dated February 16, 2024, by and between the Issuer, XOMA Corporation and XRA 1 Corp. (the "Merger Agreement") in exchange for one non-transferable contingent value right ("CVR") for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was cancelled pursuant to that certain Agreement and Plan of Merger, dated February 16, 2024, by and between the Issuer, XOMA Corporation and XRA 1 Corp. (the "Merger Agreement") in exchange for one non-transferable contingent value right ("CVR") for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 04, 2023 Filed Jan 6, 2023 21:05 UTC | PRECIGEN, INC. PGEN · Entity 4356 | Exercise / conversionRestricted Stock Units · Derivative | 17,665 | $0.00 | $0.00 |
DisclosureSEC source: 0000950103-23-000200 · dp186714_4-sabzevari.xml · derivative · entry 2 Sabzevari Helen · CIK 0001724195 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,665 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Precigen common stock. F2 · derivative.exercise_date: The RSUs were granted on January 4, 2019 and January 25, 2019 and have vested in full. F2 · derivative.expiration_date: The RSUs were granted on January 4, 2019 and January 25, 2019 and have vested in full. Read SEC document |
| January 04, 2023 Filed Jan 6, 2023 21:05 UTC | PRECIGEN, INC. PGEN · Entity 4356 | Exercise / conversionCommon Stock | 17,665 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950103-23-000200 · dp186714_4-sabzevari.xml · nonDerivative · entry 1 Sabzevari Helen · CIK 0001724195 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 914,756 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Precigen common stock. Read SEC document |
| June 13, 2022 Filed Jun 15, 2022 17:01 UTC | Kinnate Biopharma Inc. KNTE · Entity 92187 | GrantStock Option (right to buy) · Derivative | 20,250 | $0.00 Strike: $8.38 | $0.00 |
DisclosureSEC source: 0001209191-22-037029 · doc4.xml · derivative · entry 1 Sabzevari Helen · CIK 0001724195 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,250 Underlying: Common Stock · 20,250 shares Expires 2032-06-13 F1 · derivative.exercise_date: 1/12th of the shares underlying the Option vest and become exercisable on a monthly basis starting July 13, 2022 (the Vest Base Date) and thereafter on the same day of the month as the Vest Base Date or if earlier, the day immediately before the date of the next Annual Meeting of Stockholders that occurs after the Vest Base Date. Read SEC document |
| May 13, 2022 Filed May 16, 2022 22:57 UTC | PRECIGEN, INC. PGEN · Entity 4356 | SaleCommon Stock | 177,968 | $1.19 | $210,927.67 |
DisclosureSEC source: 0000950103-22-008541 · dp173213_4-sabzevari.xml · nonDerivative · entry 2 Sabzevari Helen · CIK 0001724195 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 897,091 F2 · kind: This sale was effected pursuant to the terms of a 10b5-1 plan adopted by the reporting person and was made in order to pay the tax liability arising from the vesting of RSUs. Read SEC document |
| May 12, 2022 Filed May 16, 2022 22:57 UTC | PRECIGEN, INC. PGEN · Entity 4356 | Exercise / conversionRestricted Stock Units · Derivative | 340,909 | $0.00 | $0.00 |
DisclosureSEC source: 0000950103-22-008541 · dp173213_4-sabzevari.xml · derivative · entry 3 Sabzevari Helen · CIK 0001724195 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 340,909 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Precigen common stock. F3 · derivative.exercise_date: The RSUs were granted on March 18, 2022 and have vested in full. F3 · derivative.expiration_date: The RSUs were granted on March 18, 2022 and have vested in full. Read SEC document |
| May 12, 2022 Filed May 16, 2022 22:57 UTC | PRECIGEN, INC. PGEN · Entity 4356 | Exercise / conversionCommon Stock | 340,909 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950103-22-008541 · dp173213_4-sabzevari.xml · nonDerivative · entry 1 Sabzevari Helen · CIK 0001724195 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,075,059 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Precigen common stock. Read SEC document |
| March 18, 2022 Filed Mar 22, 2022 21:03 UTC | PRECIGEN, INC. PGEN · Entity 4356 | GrantRestricted Stock Units · Derivative | 340,909 | $0.00 | $0.00 |
DisclosureSEC source: 0000950103-22-005051 · dp169631_4-sabzevari.xml · derivative · entry 1 Sabzevari Helen · CIK 0001724195 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 340,909 Underlying: Common Stock · 340,909 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Precigen common stock. F2 · derivative.exercise_date: The RSUs vest in full on May 12, 2022. F2 · derivative.expiration_date: The RSUs vest in full on May 12, 2022. Read SEC document |
| February 02, 2022 Filed Feb 4, 2022 22:06 UTC | PRECIGEN, INC. PGEN · Entity 4356 | GrantOption to Purchase Common Stock (Right to Buy) · Derivative | 847,000 | $0.00 Strike: $2.33 | $0.00 |
DisclosureSEC source: 0000950103-22-002079 · dp166687_4-sabzevari.xml · derivative · entry 1 Sabzevari Helen · CIK 0001724195 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 847,000 Underlying: Common Stock · 847,000 shares Expires 2032-02-02 F1 · derivative.exercise_date: The option vests in four equal installments on each of February 2, 2023, February 2, 2024, February 2, 2025 and February 2, 2026. Read SEC document |
| January 05, 2022 Filed Jan 6, 2022 22:08 UTC | PRECIGEN, INC. PGEN · Entity 4356 | SaleCommon Stock | 5,603 | $3.59 | $20,115.33 |
DisclosureSEC source: 0000950103-22-000271 · dp164823_4-sabzevari.xml · nonDerivative · entry 3 Sabzevari Helen · CIK 0001724195 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 734,150 F2 · kind: This sale was effected pursuant to the terms of a 10b5-1 plan adopted by the reporting person and was made in order to pay the tax liability arising from the vesting of RSUs. Read SEC document |
| January 05, 2022 Filed Jan 6, 2022 22:08 UTC | PRECIGEN, INC. PGEN · Entity 4356 | SaleCommon Stock | 1,357 | $3.59 | $4,871.63 |
DisclosureSEC source: 0000950103-22-000271 · dp164823_4-sabzevari.xml · nonDerivative · entry 2 Sabzevari Helen · CIK 0001724195 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 739,753 F2 · kind: This sale was effected pursuant to the terms of a 10b5-1 plan adopted by the reporting person and was made in order to pay the tax liability arising from the vesting of RSUs. Read SEC document |
| January 04, 2022 Filed Jan 6, 2022 22:08 UTC | PRECIGEN, INC. PGEN · Entity 4356 | Exercise / conversionRestricted Stock Units · Derivative | 17,667 | $0.00 | $0.00 |
DisclosureSEC source: 0000950103-22-000271 · dp164823_4-sabzevari.xml · derivative · entry 4 Sabzevari Helen · CIK 0001724195 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,665 Underlying: Common Stock · 17,667 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Precigen common stock. F3 · derivative.exercise_date: The RSUs were granted on January 4, 2019 and January 25, 2019 and the remaining RSUs vest on January 4, 2023. F3 · derivative.expiration_date: The RSUs were granted on January 4, 2019 and January 25, 2019 and the remaining RSUs vest on January 4, 2023. Read SEC document |
| January 04, 2022 Filed Jan 6, 2022 22:08 UTC | PRECIGEN, INC. PGEN · Entity 4356 | Exercise / conversionCommon Stock | 17,667 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950103-22-000271 · dp164823_4-sabzevari.xml · nonDerivative · entry 1 Sabzevari Helen · CIK 0001724195 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 741,110 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Precigen common stock. Read SEC document |
| January 03, 2022 Filed Jan 4, 2022 22:07 UTC | PRECIGEN, INC. PGEN · Entity 4356 | SaleCommon Stock | 3,848 | $3.67 | $14,122.54 |
DisclosureSEC source: 0000950103-22-000138 · dp164713_4-sabzevari.xml · nonDerivative · entry 2 Sabzevari Helen · CIK 0001724195 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 723,443 F2 · kind: This sale was effected pursuant to the terms of a 10b5-1 plan adopted by the reporting person and was made in order to pay the tax liability arising from the vesting of RSUs. Read SEC document |
| January 02, 2022 Filed Jan 4, 2022 22:07 UTC | PRECIGEN, INC. PGEN · Entity 4356 | Exercise / conversionRestricted Stock Units · Derivative | 9,765 | $0.00 | $0.00 |
DisclosureSEC source: 0000950103-22-000138 · dp164713_4-sabzevari.xml · derivative · entry 3 Sabzevari Helen · CIK 0001724195 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,765 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Precigen common stock. F3 · derivative.exercise_date: The RSUs were granted on January 2, 2018 and have vested in full. F3 · derivative.expiration_date: The RSUs were granted on January 2, 2018 and have vested in full. Read SEC document |
| January 02, 2022 Filed Jan 4, 2022 22:07 UTC | PRECIGEN, INC. PGEN · Entity 4356 | Exercise / conversionCommon Stock | 9,765 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950103-22-000138 · dp164713_4-sabzevari.xml · nonDerivative · entry 1 Sabzevari Helen · CIK 0001724195 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 727,291 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Precigen common stock. Read SEC document |
| July 19, 2021 Filed Jul 20, 2021 22:11 UTC | PRECIGEN, INC. PGEN · Entity 4356 | SaleCommon Stock | 12,531 | $5.43 | $68,047.09 |
DisclosureSEC source: 0000950103-21-010821 · dp154661_4-sabzevari.xml · nonDerivative · entry 2 Sabzevari Helen · CIK 0001724195 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 717,526 F2 · kind: This sale was effected pursuant to the terms of a 10b5-1 plan adopted by the reporting person and was made in order to pay the tax liability arising from the vesting of RSUs. Read SEC document |
| July 17, 2021 Filed Jul 20, 2021 22:11 UTC | PRECIGEN, INC. PGEN · Entity 4356 | Exercise / conversionRestricted Stock Units · Derivative | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950103-21-010821 · dp154661_4-sabzevari.xml · derivative · entry 3 Sabzevari Helen · CIK 0001724195 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ('RSU") represents a contingent right to receive one share of Precigen common stock. F3 · derivative.exercise_date: The RSUs were granted on March 28, 2018 and have vested in full. F3 · derivative.expiration_date: The RSUs were granted on March 28, 2018 and have vested in full. Read SEC document |
| July 17, 2021 Filed Jul 20, 2021 22:11 UTC | PRECIGEN, INC. PGEN · Entity 4356 | Exercise / conversionCommon Stock | 25,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950103-21-010821 · dp154661_4-sabzevari.xml · nonDerivative · entry 1 Sabzevari Helen · CIK 0001724195 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 730,057 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ('RSU") represents a contingent right to receive one share of Precigen common stock. Read SEC document |
| June 24, 2021 Filed Jun 28, 2021 13:04 UTC | Kinnate Biopharma Inc. KNTE · Entity 92187 | GrantStock Option (right to buy) · Derivative | 40,501 | $0.00 Strike: $24.38 | $0.00 |
DisclosureSEC source: 0001209191-21-043448 · doc4.xml · derivative · entry 1 Sabzevari Helen · CIK 0001724195 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,501 Underlying: Common Stock · 40,501 shares Expires 2031-06-24 F1 · derivative.exercise_date: 1/36th of the shares underlying the Option vest and become exercisable on each monthly anniversary of the Date of Grant. Read SEC document |
| May 13, 2021 Filed May 14, 2021 22:43 UTC | PRECIGEN, INC. PGEN · Entity 4356 | SaleCommon Stock | 47,433 | $6.40 | $303,571.20 |
DisclosureSEC source: 0000950103-21-007276 · dp151110_4-sabzevari.xml · nonDerivative · entry 2 Sabzevari Helen · CIK 0001724195 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 705,057 F2 · kind: This sale was effected pursuant to the terms of a 10b5-1 plan adopted by the reporting person and was made in order to pay the tax liability arising from the vesting of RSUs. Read SEC document |
| May 12, 2021 Filed May 14, 2021 22:43 UTC | PRECIGEN, INC. PGEN · Entity 4356 | Exercise / conversionRestricted Stock Units · Derivative | 97,276 | $0.00 | $0.00 |
DisclosureSEC source: 0000950103-21-007276 · dp151110_4-sabzevari.xml · derivative · entry 3 Sabzevari Helen · CIK 0001724195 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 97,276 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ('RSU") represents a contingent right to receive one share of Precigen common stock. F3 · derivative.exercise_date: The RSUs were granted on March 25, 2021 and have vested in full. F3 · derivative.expiration_date: The RSUs were granted on March 25, 2021 and have vested in full. Read SEC document |
| May 12, 2021 Filed May 14, 2021 22:43 UTC | PRECIGEN, INC. PGEN · Entity 4356 | Exercise / conversionCommon Stock | 97,276 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950103-21-007276 · dp151110_4-sabzevari.xml · nonDerivative · entry 1 Sabzevari Helen · CIK 0001724195 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 752,490 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ('RSU") represents a contingent right to receive one share of Precigen common stock. Read SEC document |
| March 25, 2021 Filed Mar 29, 2021 23:53 UTC | PRECIGEN, INC. PGEN · Entity 4356 | GrantRestricted Stock Units · Derivative | 97,276 | $0.00 | $0.00 |
DisclosureSEC source: 0001123292-21-000571 · edgar.xml · derivative · entry 1 Sabzevari Helen · CIK 0001724195 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,276 Underlying: Common Stock · 97,276 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ('RSU") represents a contingent right to receive one share of Precigen common stock. F2 · derivative.exercise_date: The RSUs vest in full on May 12, 2021. F2 · derivative.expiration_date: The RSUs vest in full on May 12, 2021. Read SEC document |
| January 06, 2021 Filed Jan 7, 2021 21:26 UTC | PRECIGEN, INC. PGEN · Entity 4356 | SaleCommon Stock | 260,045 | $8.92 | $2,318,535.22 |
DisclosureSEC source: 0001123292-21-000061 · edgar.xml · nonDerivative · entry 2 Sabzevari Helen · CIK 0001724195 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 655,214 F2 · kind: This sale was effected pursuant to the terms of a 10b5-1 plan adopted by the reporting person and was made in order to pay the tax liability arising from the vesting of RSUs. Read SEC document |
| January 05, 2021 Filed Jan 6, 2021 21:37 UTC | PRECIGEN, INC. PGEN · Entity 4356 | SaleCommon Stock | 9,040 | $10.56 | $95,506.70 |
DisclosureSEC source: 0001123292-21-000057 · edgar.xml · nonDerivative · entry 2 Sabzevari Helen · CIK 0001724195 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 415,259 F2 · kind: This sale was effected pursuant to the terms of a 10b5-1 plan adopted by the reporting person and was made in order to pay the tax liability arising from the vesting of RSUs. Read SEC document |
| January 05, 2021 Filed Jan 7, 2021 21:26 UTC | PRECIGEN, INC. PGEN · Entity 4356 | Exercise / conversionRestricted Stock Units · Derivative | 500,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001123292-21-000061 · edgar.xml · derivative · entry 3 Sabzevari Helen · CIK 0001724195 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 500,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ('RSU") represents a contingent right to receive one share of Precigen common stock. F3 · derivative.exercise_date: The RSUs were granted on January 5, 2020 and have vested in full. F3 · derivative.expiration_date: The RSUs were granted on January 5, 2020 and have vested in full. Read SEC document |
| January 05, 2021 Filed Jan 7, 2021 21:26 UTC | PRECIGEN, INC. PGEN · Entity 4356 | Exercise / conversionCommon Stock | 500,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001123292-21-000061 · edgar.xml · nonDerivative · entry 1 Sabzevari Helen · CIK 0001724195 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 915,259 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ('RSU") represents a contingent right to receive one share of Precigen common stock. Read SEC document |
| January 04, 2021 Filed Jan 5, 2021 22:33 UTC | PRECIGEN, INC. PGEN · Entity 4356 | SaleCommon Stock | 5,279 | $10.16 | $53,634.64 |
DisclosureSEC source: 0001123292-21-000034 · edgar.xml · nonDerivative · entry 2 Sabzevari Helen · CIK 0001724195 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 406,632 F2 · kind: This sale was effected pursuant to the terms of a 10b5-1 plan adopted by the reporting person and was made in order to pay the tax liability arising from the vesting of RSUs. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 21:37 UTC | PRECIGEN, INC. PGEN · Entity 4356 | Exercise / conversionRestricted Stock Units · Derivative | 17,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001123292-21-000057 · edgar.xml · derivative · entry 3 Sabzevari Helen · CIK 0001724195 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,332 Underlying: Common Stock · 17,667 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ('RSU") represents a contingent right to receive one share of Precigen common stock. F3 · derivative.exercise_date: The RSUs were granted on January 4, 2019 and January 25, 2019, and the remaining RSUs vest in two equal annual installments on each of January 4, 2022 and 2023. F3 · derivative.expiration_date: The RSUs were granted on January 4, 2019 and January 25, 2019, and the remaining RSUs vest in two equal annual installments on each of January 4, 2022 and 2023. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 21:37 UTC | PRECIGEN, INC. PGEN · Entity 4356 | Exercise / conversionCommon Stock | 17,667 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001123292-21-000057 · edgar.xml · nonDerivative · entry 1 Sabzevari Helen · CIK 0001724195 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 424,299 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ('RSU") represents a contingent right to receive one share of Precigen common stock. Read SEC document |
| January 02, 2021 Filed Jan 5, 2021 22:33 UTC | PRECIGEN, INC. PGEN · Entity 4356 | Exercise / conversionRestricted Stock Units · Derivative | 9,766 | $0.00 | $0.00 |
DisclosureSEC source: 0001123292-21-000034 · edgar.xml · derivative · entry 3 Sabzevari Helen · CIK 0001724195 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,765 Underlying: Common Stock · 9,766 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted unit ("RSU") represents a contingent right to receive one share of Precigen common stock. F3 · derivative.exercise_date: The RSUs were granted on January 2, 2018, and the remaining RSUs vest on January 2, 2022. F3 · derivative.expiration_date: The RSUs were granted on January 2, 2018, and the remaining RSUs vest on January 2, 2022. Read SEC document |
| January 02, 2021 Filed Jan 5, 2021 22:33 UTC | PRECIGEN, INC. PGEN · Entity 4356 | Exercise / conversionCommon Stock | 9,766 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001123292-21-000034 · edgar.xml · nonDerivative · entry 1 Sabzevari Helen · CIK 0001724195 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 411,911 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted unit ("RSU") represents a contingent right to receive one share of Precigen common stock. Read SEC document |
| July 20, 2020 Filed Jul 21, 2020 22:40 UTC | PRECIGEN, INC. PGEN · Entity 4356 | SaleCommon Stock | 12,220 | $4.58 | $55,967.60 |
DisclosureSEC source: 0001123292-20-000987 · edgar.xml · nonDerivative · entry 2 Sabzevari Helen · CIK 0001724195 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 402,145 F2 · kind: This sale was effected pursuant to the terms of a 10b5-1 plan adopted by the reporting person and was made in order to pay the tax liability arising from the vesting of restricted stock units. Read SEC document |
| July 17, 2020 Filed Jul 21, 2020 22:40 UTC | PRECIGEN, INC. PGEN · Entity 4356 | Exercise / conversionRestricted Stock Units · Derivative | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001123292-20-000987 · edgar.xml · derivative · entry 3 Sabzevari Helen · CIK 0001724195 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Precigen common stock. F3 · derivative.exercise_date: The restricted stock units were granted on March 28, 2018 and the remaining restricted stock units vest on July 17, 2021. F3 · derivative.expiration_date: The restricted stock units were granted on March 28, 2018 and the remaining restricted stock units vest on July 17, 2021. Read SEC document |
| July 17, 2020 Filed Jul 21, 2020 22:40 UTC | PRECIGEN, INC. PGEN · Entity 4356 | Exercise / conversionCommon Stock | 25,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001123292-20-000987 · edgar.xml · nonDerivative · entry 1 Sabzevari Helen · CIK 0001724195 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 414,365 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Precigen common stock. Read SEC document |
| May 15, 2020 Filed May 18, 2020 20:04 UTC | PRECIGEN, INC. PGEN · Entity 4356 | SaleCommon Stock | 217,527 | $2.37 | $515,800.02 |
DisclosureSEC source: 0001123292-20-000724 · edgar.xml · nonDerivative · entry 2 Sabzevari Helen · CIK 0001724195 · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 389,365 F2 · kind: This sale was effected pursuant to the terms of a 10b5-1 plan adopted by the reporting person and was made in order to pay the tax liability arising from the vesting of restricted stock units. Read SEC document |
| May 14, 2020 Filed May 18, 2020 20:04 UTC | PRECIGEN, INC. PGEN · Entity 4356 | Exercise / conversionRestricted Stock Units · Derivative | 500,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001123292-20-000724 · edgar.xml · derivative · entry 3 Sabzevari Helen · CIK 0001724195 · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 500,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Precigen common stock. F3 · derivative.exercise_date: The restricted stock units were granted on March 23, 2020 and have vested in full. F3 · derivative.expiration_date: The restricted stock units were granted on March 23, 2020 and have vested in full. Read SEC document |
| May 14, 2020 Filed May 18, 2020 20:04 UTC | PRECIGEN, INC. PGEN · Entity 4356 | Exercise / conversionCommon Stock | 500,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001123292-20-000724 · edgar.xml · nonDerivative · entry 1 Sabzevari Helen · CIK 0001724195 · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 606,892 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Precigen common stock. Read SEC document |
| April 01, 2020 Filed Apr 2, 2020 20:37 UTC | PRECIGEN, INC. PGEN · Entity 4356 | SaleCommon Stock | 5,450 | $3.01 | $16,414.86 |
DisclosureSEC source: 0001123292-20-000640 · edgar.xml · nonDerivative · entry 2 Sabzevari Helen · CIK 0001724195 · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,892 F2 · kind: This sale was effected pursuant to the terms of a 10b5-1 plan adopted by the reporting person and was made in order to pay the tax liability arising from the vesting of restricted stock units. Read SEC document |
| March 31, 2020 Filed Apr 2, 2020 20:37 UTC | PRECIGEN, INC. PGEN · Entity 4356 | Exercise / conversionRestricted Stock Units · Derivative | 14,340 | $0.00 | $0.00 |
DisclosureSEC source: 0001123292-20-000640 · edgar.xml · derivative · entry 3 Sabzevari Helen · CIK 0001724195 · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,340 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Precigen common stock. F3 · derivative.exercise_date: The restricted stock units were granted on April 9, 2019 and have vested in full. F3 · derivative.expiration_date: The restricted stock units were granted on April 9, 2019 and have vested in full. Read SEC document |
| March 31, 2020 Filed Apr 2, 2020 20:37 UTC | PRECIGEN, INC. PGEN · Entity 4356 | Exercise / conversionCommon Stock | 14,340 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001123292-20-000640 · edgar.xml · nonDerivative · entry 1 Sabzevari Helen · CIK 0001724195 · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,342 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Precigen common stock. Read SEC document |
| March 23, 2020 Filed Mar 23, 2020 20:39 UTC | PRECIGEN, INC. PGEN · Entity 4356 | GrantRestricted Stock Units · Derivative | 500,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001123292-20-000608 · edgar.xml · derivative · entry 1 Sabzevari Helen · CIK 0001724195 · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Precigen common stock. F2 · derivative.exercise_date: The RSUs vest in full on May 14, 2020. F2 · derivative.expiration_date: The RSUs vest in full on May 14, 2020. Read SEC document |
| January 06, 2020 Filed Jan 7, 2020 22:13 UTC | PRECIGEN, INC. XON · Entity 4356 | SaleCommon Stock | 6,732 | $5.83 | $39,242.85 |
DisclosureSEC source: 0001123292-20-000110 · edgar.xml · nonDerivative · entry 2 Sabzevari Helen · CIK 0001724195 · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,002 F2 · kind: This sale was effected pursuant to the terms of a 10b5-1 plan adopted by the reporting person and was made in order to pay the tax liability arising from the vesting of restricted stock units. Read SEC document |
| January 05, 2020 Filed Jan 7, 2020 22:13 UTC | PRECIGEN, INC. XON · Entity 4356 | GrantOption to Purchase Common Stock (Right to Buy) · Derivative | 1,500,000 | $0.00 Strike: $17.85 | $0.00 |
DisclosureSEC source: 0001123292-20-000110 · edgar.xml · derivative · entry 7 Sabzevari Helen · CIK 0001724195 · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,500,000 Underlying: Common Stock · 1,500,000 shares Expires 2030-01-05 F6 · derivative.exercise_date: The option vests in four equal annual installments beginning on January 5, 2021. Read SEC document |
| January 05, 2020 Filed Jan 7, 2020 22:13 UTC | PRECIGEN, INC. XON · Entity 4356 | GrantOption to Purchase Common Stock (Right to Buy) · Derivative | 1,500,000 | $0.00 Strike: $11.90 | $0.00 |
DisclosureSEC source: 0001123292-20-000110 · edgar.xml · derivative · entry 6 Sabzevari Helen · CIK 0001724195 · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,500,000 Underlying: Common Stock · 1,500,000 shares Expires 2030-01-05 F6 · derivative.exercise_date: The option vests in four equal annual installments beginning on January 5, 2021. Read SEC document |
| January 05, 2020 Filed Jan 7, 2020 22:13 UTC | PRECIGEN, INC. XON · Entity 4356 | GrantOption to Purchase Common Stock (Right to Buy) · Derivative | 1,500,000 | $0.00 Strike: $5.95 | $0.00 |
DisclosureSEC source: 0001123292-20-000110 · edgar.xml · derivative · entry 5 Sabzevari Helen · CIK 0001724195 · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,500,000 Underlying: Common Stock · 1,500,000 shares Expires 2030-01-05 F5 · derivative.exercise_date: The option vests in four installments as follows: 50% on January 5, 2021, and the remaining 50% in three equal annual installments on each of January 5, 2022, 2023, and 2024. Read SEC document |
| January 05, 2020 Filed Jan 7, 2020 22:13 UTC | PRECIGEN, INC. XON · Entity 4356 | GrantRestricted Stock Units · Derivative | 500,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001123292-20-000110 · edgar.xml · derivative · entry 4 Sabzevari Helen · CIK 0001724195 · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of XON common stock. F4 · derivative.exercise_date: The restricted stock units vest in full on January 5, 2021. F4 · derivative.expiration_date: The restricted stock units vest in full on January 5, 2021. Read SEC document |
| January 04, 2020 Filed Jan 7, 2020 22:13 UTC | PRECIGEN, INC. XON · Entity 4356 | Exercise / conversionRestricted Stock Units · Derivative | 17,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001123292-20-000110 · edgar.xml · derivative · entry 3 Sabzevari Helen · CIK 0001724195 · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,999 Underlying: Common Stock · 17,667 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of XON common stock. F3 · derivative.exercise_date: The restricted stock units were granted on January 4, 2019 and January 25, 2019, and the remaining restricted stock units vest in three equal annual installments on each of January 4, 2021, 2022, and 2023. F3 · derivative.expiration_date: The restricted stock units were granted on January 4, 2019 and January 25, 2019, and the remaining restricted stock units vest in three equal annual installments on each of January 4, 2021, 2022, and 2023. Read SEC document |
| January 04, 2020 Filed Jan 7, 2020 22:13 UTC | PRECIGEN, INC. XON · Entity 4356 | Exercise / conversionCommon Stock | 17,667 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001123292-20-000110 · edgar.xml · nonDerivative · entry 1 Sabzevari Helen · CIK 0001724195 · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,734 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of XON common stock. Read SEC document |
| January 03, 2020 Filed Jan 6, 2020 21:16 UTC | PRECIGEN, INC. XON · Entity 4356 | SaleCommon Stock | 3,886 | $5.77 | $22,421.44 |
DisclosureSEC source: 0001123292-20-000069 · edgar.xml · nonDerivative · entry 2 Sabzevari Helen · CIK 0001724195 · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,067 F2 · kind: This sale was effected pursuant to the terms of a 10b5-1 plan adopted by the reporting person and was made in order to pay the tax liability arising from the vesting of restricted stock units. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.